Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Current Opinion in Immunology|February 2, 2016
Adoptive cell therapy: a highly successful individualized therapy for melanoma with great potential for other malignanciesEls M E VerdegaalFrontiers in Immunology|September 30, 2017
The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for ImmunotherapyEls M E Verdegaal, Sjoerd H van der BurgCancer Immunology, Immunotherapy : CII|April 13, 2017
IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanomaSara M Melief, Marten Visser, Sjoerd H van der Burg, et al.International Journal of Molecular Sciences|January 11, 2022
The ABCs of Antigen Presentation by Stromal Non-Professional Antigen-Presenting CellsTom J Harryvan, Sabine de Lange, Lukas J A C Hawinkels, et al.Journal of Clinical Medicine|November 17, 2019
Targeting of the Cancer-Associated Fibroblast-T-Cell Axis in Solid MalignanciesTom J Harryvan, Els M E Verdegaal, James C H Hardwick, et al.Cytokine|January 10, 2013
Inhibition of the type I immune responses of human monocytes by IFN-α and IFN-βRoelof A de Paus, Annelies van Wengen, Iris Schmidt, et al.Pigment Cell & Melanoma Research|April 8, 2014
Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanomaJoanna Kaplon, Cornelia Hömig-Hölzel, Linda Gao, et al.Oncotarget|September 15, 2017
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanomaJinfeng Cao, Niels J Brouwer, Kate E Richards, et al.The Journal of Experimental Medicine|August 18, 2018
Identification of non-mutated neoantigens presented by TAP-deficient tumorsKoen A Marijt, Laura Blijleven, Els M E Verdegaal, et al.Cancer Immunology Research|November 15, 2018
Autoantibody Development under Treatment with Immune-Checkpoint InhibitorsEmma C de Moel, Elisa A Rozeman, Ellen H Kapiteijn, et al.Pageof 4